ResoTher Pharma ApS, Holte, Denmark, announces today that the shareholders has elected two new members to the company’s Board of Directors at the Annual General Meeting held May 31st, 2021.

Thomas Feldhus, MBA, a Copenhagen-based life science executive joins the ResoTher Pharma Board of Directors with over 20 years of experience in biotech, including C-suite management in several listed companies. Mr. Feldthus has a background in life science finance and investing. He is co-founder of Saniona (SANION, Nasdaq OMX), Scandion Oncology (SCAN, Nasdaq First North), Initiator Pharma (INIT, Spotlight), Symphogen (acq. by Servier), Ataxion (acq. by Novartis) and Leukotech (acq. by Hansa Biopharma). Previously, Mr. Feldthus served as vVD and CFO of Saniona. Prior to that he was CFO of Symphogen, Corporate Development Manager at Novo Nordisk and Investment Associate at Novo A/S. Mr. Feldthus currently serves on the board of Scandion Oncology.

Also newly elected to the ResoTher Pharma Board of Directors is Sven Jacobson, MBA, a New York-based biotech entrepreneur with extensive management and transaction experience within the life science industry, including cardiovascular and acute hospital-based indications. Mr. Jacobson has co-founded and serves as CEO of Remedy Pharmaceuticals, Martin Pharmaceuticals, and Woolsey Pharmaceuticals, all privately held, clinical stage pharmaceutical companies. Previously, Mr. Jacobson co-founded and served on the board of Access Scientific, Cure Therapeutics and St. Camillus Medical. Mr. Jacobson is currently a member of the Board of Directors of Critical Diagnostics and a Partner at Carrot Capital Healthcare Ventures.

Lars Stigel, CEO of CAPNOVA, a Danish seed fund that invested in ResoTher at an early stage, steps down from the ResoTher Board of Directors.

“We would like to thank Lars for his tenure and are pleased to welcome Sven and Thomas to our Board of Directors at this important next stage of ResoTher Pharma’s evolution,” stated Kirsten Drejer, Chairman of the Board of Directors of ResoTher Pharma’s. “I am confident that the addition of Thomas and Sven will help us execute on ResoTher Pharma’s important mission, to bring a new and effective treatment option to market for patients with Myocardial Infarct.”

Thomas Feldthus expressed his motivations for joining the Board “I am very pleased to be joining the Board of ResoTher Pharma. The company has a highly experienced management team and an advanced drug candidate based on an interesting new mode of action that addresses a significant medical need. Resolution therapy is now coming of age with proof of concept in other in inflammatory indications and ResoTher has a very interesting journey ahead.”

Sven Jacobson added “I am delighted to join the Board and look forward to working with ResoTher’s leadership team and my fellow Board members as the company seeks to translate its strong preclinical findings into clinically meaningful results in this important and neglected indication.”